Heterogeneity of IGF-1 Levels in Children with hCG-Induced Precocious Puberty
Open Access
- 15 November 2022
- journal article
- research article
- Published by Hindawi Limited in International Journal of Endocrinology
- Vol. 2022, 1-6
Abstract
Objective. Sex steroid stimulates growth hormone release during puberty. However, the role of IGF-1 levels in human-chorionic-gonadotropin-induced precocious puberty remains unclear. Methods. A retrospective study reviewing thirty patients with precocious puberty due to human-chorionic-gonadotropin-secreting intracranial germ cell tumors was performed. Changes in IGF-1 levels were collected. Result. All patients included were boys. At diagnosis, the median IGF-1 standard deviation was 0.87 (0.1, 1.87). When human-chorionic-gonadotropin normalized, the median IGF-1 standard deviation was 1.58 (−0.53, 2.55), which is slightly higher than baseline ( ). When patients completed their therapeutic plan, the median IGF-1 standard deviation was 0.10 (−1.05, 0.68), which was significantly lower than that of baseline ( ) and of human-chorionic-gonadotropin being normalized ( ). At the last visit, the mean IGF-1 standard deviation was −1.11(−1.97, 0.76), which is slightly lower than that of baseline ( ) and post-therapy levels ( ), but significantly lower than that of human-chorionic-gonadotropin being normalized. Two patients had IGF-1 levels above 2 standard deviations at diagnosis, eight at the time when human-chorionic-gonadotropin normalized, and two at the end of therapy. Only one patient had an IGF-1 level below 2 standard deviations at diagnosis and at the time when human-chorionic-gonadotropin normalized, and two patients at the end of therapy. At the last follow-up, all patients had normal IGF-1 levels. Conclusion. IGF-1 levels in patients with human-chorionic-gonadotropin-induced precocious puberty have heterogeneity, but IGF-1 standard deviations are mostly within the normal range. If elevated, it might decline later with a decrease in human-chorionic-gonadotropin level. IGF-1 levels seem not valuable enough to assess human-chorionic-gonadotropin-induced precocity regression.Keywords
This publication has 21 references indexed in Scilit:
- Modulation of growth hormone action by sex steroidsClinical Endocrinology, 2006
- Are Growth Factors and Leptin Involved in the Pathogenesis of Premature Adrenarche in Girls?Journal of Pediatric Endocrinology and Metabolism, 2005
- Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 in Girls with Premature ThelarcheJournal of Pediatric Endocrinology and Metabolism, 2003
- The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor-Binding Protein Complex in Girls with Central Precocious Puberty before and during Gonadotropin-Releasing Hormone Analog TherapyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Estrogen and Testosterone, But Not a Nonaromatizable Androgen, Direct Network Integration of the Hypothalamo-Somatotrope (Growth Hormone)-Insulin-Like Growth Factor I Axis in the Human: Evidence from Pubertal Pathophysiology and Sex-Steroid Hormone ReplacementThe Journal of Clinical Endocrinology & Metabolism, 1997
- Estrogen and Testosterone, But Not a Nonaromatizable Androgen, Direct Network Integration of the Hypothalamo-Somatotrope (Growth Hormone)-Insulin-Like Growth Factor I Axis in the Human: Evidence from Pubertal Pathophysiology and Sex-Steroid Hormone Replacement1The Journal of Clinical Endocrinology & Metabolism, 1997
- Influence of Hypothalamus and Ovary on Pituitary Function in Transgenic Mice Expressing the Bovine Growth Hormone Gene and in Growth Hormone-Deficient Ames Dwarf Mice1Biology of Reproduction, 1996
- Serum concentrations of free and total insulin‐like growth factor‐I, IGF binding proteins ‐1 and‐3 and IGFBP‐3 protease activity in boys with normal or precocious pubertyClinical Endocrinology, 1996
- Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).The Journal of Clinical Endocrinology & Metabolism, 1995
- Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate)The Journal of Clinical Endocrinology & Metabolism, 1995